110928-44-4

Basic information

• Product Name: (1r,4r)-methyl 4-(hydroxymethyl)cyclohexanecarboxylate
• Synonyms: (1r,4r)-methyl 4-(hydroxymethyl)cyclohexanecarboxylate;trans-Methyl 4-(hydroxyMethyl)cyclohexanecarboxylate;trans-4-(Hydroxymethyl)cyclohexanecarboxylic acid methyl ester;trans-4-(Methoxycarbonyl)cyclohexanemethanol;4-Hydroxymethyl-cyclohexanecarboxylic acid methyl ester;(1R,4R)-4-(hydroxymethyl)cyclohexanecarboxylic acid methyl ester;methyl (1r,4r)-4-(hydroxymethyl)cyclohexane-1-carboxylate;trans-(4-hydroxymethyl)cyclohexane-1-carboxylic acid methyl ester
• CAS NO: 110928-44-4
• Molecular Formula: C₉H₁₆O₃
• Molecular Weight: 172.22154
• Mol File: 110928-44-4.mol

Chemical Properties

• Boiling Point: 251℃
• Flash Point: 57℃
• Appearance: /
• Density: 1.058
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.464
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 15.05±0.10(Predicted)
• CAS DataBase Reference: (1r,4r)-methyl 4-(hydroxymethyl)cyclohexanecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (1r,4r)-methyl 4-(hydroxymethyl)cyclohexanecarboxylate(110928-44-4)
• EPA Substance Registry System: (1r,4r)-methyl 4-(hydroxymethyl)cyclohexanecarboxylate(110928-44-4)

Safety Data

• Hazardous Substances Data: 110928-44-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H16O3/c1-12-9(11)8-4-2-7(6-10)3-5-8/h7-8,10H,2-6H2,1H3

Upstream product

• 15177-67-0 trans-4-(methoxycarbonyl)cyclohexanecarboxylic acid 
• 1148130-27-1 methyl (1r,4r)-4-((benzyloxy)methyl)cyclohexanecarboxylate 
• 66185-74-8 (1r,4r)‐4‐(hydroxymethyl)cyclohexane‐1‐carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 29275-88-5 trans-(4-aminomethyl)cyclohexane-1-carboxylic acid methyl ester hydrochloride 
• 67-56-1 methanol 

Downstream Products

• 1112182-56-5 C₁₅H₁₉NO₇S 
• 1411770-34-7 trans-4-{[(4-methyl-6-{[4-(trifluoromethyl)pyridin-2-yl]amino}-2,3'-bipyridin-6'-yl)oxy]methyl}cyclohexanecarboxylic acid 
• 213413-28-6 (1R,4R)-4-(iodomethyl)cyclohexanecarboxylic acid methyl ester 
• 1456626-16-6 (1R,4R)-4-(nitromethyl)cyclohexanecarboxylic acid methyl ester 
• 1456626-17-7 6-[(1R,4R)-4-(methoxycarbonyl)cyclohexane-1-yl]-6-nitro-1,4-bis(phenylmethyl)-tetrahydro-1H-1,4-diazepine 
• 1456626-18-8 6-amino-6-[(1R,4R)-4-(methoxycarbonyl)cyclohexane-1-yl]-tetrahydro-1H-1,4-diazepine 
• 1456626-19-9 6-[bis[2-(1,1-dimethylethoxy)-2-oxoethyl]amino]-6-[(1R,4R)-4-(methoxycarbonyl)-cyclohexane-1-yl]tetrahydro-1H-1,4-diazepine-1,4(5H)-diacetic acid bis(1,1-dimethylethyl)ester 
• 1456626-21-3 6-[bis[2-[(1,1-dimethyl)ethoxy]-2-oxoethyl]amino]-6-[(1R,4R)-4-[[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl]cyclohexane-1-yl]tetrahydro-1H-1,4-diazepine-1,4(5H)-diacetic acid bis[(1,1-dimethyl)ethyl] ester 
• 1456626-22-4 6-[bis[2-[(1,1-dimethyl)ethoxy]-2-oxoethyl]amino]-6-[(1R,4R)-4-[(didecylamino)carbonyl]cyclohexane-1-yl]tetrahydro-1H-1,4-diazepine-1,4(5H)-diacetic acid bis[(1,1-dimethyl)ethyl] ester 
• 1456626-25-7 6-[bis(carboxymethyl)amino]-6-[(1R,4R)-4-[(didecylamino)-carbonyl]cyclohexane-1-yl]tetrahydro-1H-1,4-diazepine-1,4(5H) diacetic acid 
• 1456626-20-2 6-[bis[2-(1,1-dimethylethoxy)-2-oxoethyl]amino]-6-[(1R,4R)-4-carboxy-cyclohexane-1-yl]tetrahydro-1H-1,4-diazepine-1,4(5H)-diacetic acid bis(1,1-dimethylethyl)ester 
• 1112178-70-7 (1R,4R)-4-[(methylsulfonyloxy)methyl]cyclohexanecarboxylic acid methyl ester 
• 1346450-07-4 trans-(E/Z)-4-(hydroxyimino-methyl)-cyclohexanecarboxylic acid methyl ester 

Relevant articles and documents

Synthesis and Biopharmaceutical Evaluation of Imatinib Analogues Featuring Unusual Structural Motifs

A convenient synthesis of imatinib, a potent inhibitor of ABL1 kinase and widely prescribed drug for the treatment of a variety of leukemias, was devised and applied to the construction of a series of novel imatinib analogues featuring a number of non-aromatic structural motifs in place of the parent molecule's phenyl moiety. These analogues were subsequently evaluated for their biopharmaceutical properties (e.g., ABL1 kinase inhibitory activity, cytotoxicity). The bicyclo[1.1.1]pentane- and cubane-containing analogues were found to possess higher themodynamic solubility, whereas cubane- and cyclohexyl-containing analogues exhibited the highest inhibitory activity against ABL1 kinase and the most potent cytotoxicity values against cancer cell lines K562 and SUP-B15. Molecular modeling was employed to rationalize the weak activity of the compounds against ABL1 kinase, and it is likely that the observed cytotoxicity of these agents arises through off-target effects.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

CHEMICAL COMPOUNDS

The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.

NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF

The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof

Disclosed are an antibody drug conjugate IB, which uses ether linkages for connection, and improves the water solubility, stability and cytotoxicity in vivo and in intro, and an intermediate, a pharmaceutical composition, and uses of the antibody drug conjugate. The antibody drug conjugate has simple synthetic steps and a high yield.

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Hydroxypurine compound and use thereof

The invention discloses a hydroxypurine compound and a use of the hydroxypurine compound as a PDE2 or TNFa inhibitor and concretely discloses a compound shown in the formula (I) and its tautomer or pharmaceutically acceptable salt.